Biotarget: a platform to rapidly disseminate knowledge and exchange experiences in biotarget molecules

It is my pleasure and great privilege to present the starting issue of Biotarget to you. This is a new international peer-reviewed journal devoted to the rapid publication of high-quality studies related to identifying key biotarget molecules and the application of biotarget molecules in human and animal disease, available in print and online. The principal aim of Biotarget is to provide an insight for researchers to develop molecular tools and to identify molecular targets for the diagnosis and treatment of a variety of diseases (including cancer, diabetes, neurodegeneration, heart disease, inflammation, immune disease and metabolic disease etc.). Meanwhile, Biotarget is also to provide a free platform for rapid dissemination of latest original research articles as well as cutting-edge review articles in all areas related to biotarget molecules in medicine and life science.

Nowadays, more and more biological molecules are applied in medicine and life science. Biotarget strives to report the most recent advances in biotarget molecules research in wide field. Biotarget will feature: (I) original articles: reporting on novel and original findings about biotarget molecules and molecular biology; (II) review articles: both solicited and unsolicited review articles about biotarget molecules in specific field are welcome; (III) systematic review and meta-analysis; (IV) short communication; (V) perspective; (VI) correspondence; (VII) editorial; (VIII) commentary; (IX) viewpoint; (X) case report; (XI) meeting report; (XII) technical notes; (XIII) brief reports and (XIV) clinical guidelines.

All articles can be submitted electronically online. The entire submission and review process will be managed through editorial manager. Here, I am sure that the online system of AME Publishing Company of Biotarget manuscript submission and review will be straight forward and user-friendly. Our goal is to provide a prompt and efficient platform for scientific publications with outstanding editorial support. Every effort we made contributes to presenting readers of Biotarget with a new, well-constructed, informative, and educational journal.

I am honored to serve as the Editor-in-Chief of Biotarget, and very grateful to have a team of excellent scientists and physicians join the editorial board. We promise to work together diligently, and I am confident that Biotarget will continue to publish high quality papers rapidly and take the lead in the field of biotarget molecules.

At this historical moment for Biotarget, we would like to thank all our colleagues for their assistance and endeavor to make the launch of this newborn journal possible. Of course, your future support and nurture on Biotarget would be greatly appreciated. We are also grateful to our editorial board members and staff for their diligence in copy editing, paper processing and journal promotion.